Rapport Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Rapport Therapeutics, Inc. (RAPP) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $11.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- Rapport Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $14.58M, a 3117.88% increase year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$3.49M, a 1154.68% decline year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $3.69M, a 334.67% increase year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.70M, a 433.33% increase year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $6.17M, a 1561.99% increase from fiscal 2024.
- Rapport Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $371.00K, a 93.10% decline from fiscal 2023.
- Rapport Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $5.38M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $11.09M 10-Q · filed 2026-08-05 | $14.77M derived: sum of 3 quarters · filed 2026-08-05 | $16.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$3.49M 10-Q · filed 2026-05-07 | $195.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.89M derived: sum of 3 quarters · filed 2026-05-07 | $2.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $5.38M derived: sum of 2 quarters · filed 2026-03-10 | $5.83M derived: sum of 3 quarters · filed 2026-08-05 | $6.17M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.15M derived: sum of 2 quarters · filed 2026-08-05 | $2.48M 10-Q · filed 2025-11-06 | $3.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $453.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $784.00K 10-Q · filed 2026-08-05 | $1.63M derived: sum of 3 quarters · filed 2026-08-05 | $1.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $331.00K 10-Q · filed 2026-05-07 | $1.18M derived: sum of 2 quarters · filed 2026-05-07 | $1.50M derived: sum of 3 quarters · filed 2026-05-07 | $521.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $848.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.17M derived: sum of 2 quarters · filed 2026-03-10 | $190.00K derived: sum of 3 quarters · filed 2026-03-10 | $371.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$658.00K derived: sum of 2 quarters · filed 2025-11-06 | -$477.00K 10-Q · filed 2025-11-06 | $2.90M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$976.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$795.00K 10-Q · filed 2025-08-07 | $2.58M derived: sum of 3 quarters · filed 2025-08-07 | $3.69M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $181.00K 10-Q · filed 2025-05-08 | $3.56M derived: sum of 2 quarters · filed 2025-05-08 | $4.66M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $4.48M derived: sum of 2 quarters · filed 2025-03-11 | $5.38M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.00M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $898.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |